Out-licensed Assets Aldoxorubicin and Arimoclomol Rapidly Advancing into Multiple Indications of High Unmet Need
CytRx Stands to Receive Significant Future Milestone Payments and Royalties from Licensing Agreements
PR Newswire
LOS ANGELES, May 15, 2019